A Rare Phenomenon, Recurrent Acute Dystonia after Withdrawal of ‘Methylphenidate-immediate Release Form’: A Pediatric Case with ADHD
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Drug-induced acute dystonia is usually associated with combination therapies of neuroleptics, but rarely with the withdrawal or rebound effect of various psychotrops. Very sparse reports have described acute dystonia as a methylphenidate withdrawal (rebound effect), particularly in combination modalities. However, there is no case report or research regarding acute dystonia related to the withdrawal of the short-acting methylphenidate-immediate release form (MPH-IR) in the case of monotherapy of MPH-IR or a combination with guanfacine. Herein, a pediatric case of recurrent acute dystonia with two separate phenomena, locating orolingual and oromandibular/lower extremities, is presented as a withdrawal adverse reaction occurring after abrupt discontinuation of MPH-IR when under a combination therapy with guanfacine. Various options such as anticholinergic agents, re-administrating MPH, or turning to monotherapy from combination modalities, can be suggested in treatment, as well as only hydration may also have the benefit of resolving the symptoms, as in the current case. Practitioners should be aware of all possible adverse effects of MPH, even the rebound effect of short-acting forms.
Abstract
Drug-induced acute dystonia is usually associated with combination therapies of neuroleptics, but rarely with the withdrawal or rebound effect of various psychotrops. Very sparse reports have described acute dystonia as a methylphenidate withdrawal (rebound effect), particularly in combination modalities. However, there is no case report or research regarding acute dystonia related to the withdrawal of the short-acting methylphenidate-immediate release form (MPH-IR) in the case of monotherapy of MPH-IR or a combination with guanfacine. Herein, a pediatric case of recurrent acute dystonia with two separate phenomena, locating orolingual and oromandibular/lower extremities, is presented as a withdrawal adverse reaction occurring after abrupt discontinuation of MPH-IR when under a combination therapy with guanfacine. Various options such as anticholinergic agents, re-administrating MPH, or turning to monotherapy from combination modalities, can be suggested in treatment, as well as only hydration may also have the benefit of resolving the symptoms, as in the current case. Practitioners should be aware of all possible adverse effects of MPH, even the rebound effect of short-acting forms.
참고문헌 (19)
- Uzun ME, "Methylphenidate induced acute dystonic reaction", Indian J Pediatr, 85, pp.577~ (2018)
- Tsang K, "Drug-induced movement disorders", Med Bull, 13, pp.4~5 (2008)
- Verghese C, "Methylphenidate" (2022), StatPearls Publishing
- Yilmaz AE, "Methylphenidate-induced acute orofacial and extremity dyskinesia", J Child Neurol, 28, pp.781~783 (2013)
- Waugh JL, "Acute dyskinetic reaction in a healthy toddler following methylphenidate ingestion", Pediatr Neurol, 49, pp.58~60 (2013)
- Rissardo JP, "Oromandibular dystonia secondary to methylphenidate : a case report and literature review", Int Arch Health Sci, 7, pp.108~111 (2020)
- Sahin N, "Methylphenidate-induced oculogyric crisis in a patient with autism spectrum disorder and attention deficit hyperactivity disorder : a case report", Psychiatry Clin Psychopharmacol, 30, pp.461~463 (2020)
- Grau-López L, "Dystonia in methylphenidate withdrawal : a case report", J Addict Med, 11, pp.154~156 (2017)
- Keshen A, "Acute dystonic reaction in an adolescent on risperidone when a concomitant stimulant medication is discontinued", J Child Adolesc Psychopharmacol, 17, pp.867~870 (2007)
- Benjamin E, "Stimulant-atypical antipsychotic interaction and acute dystonia", J Am Acad Child Adolesc Psychiatry, 44, pp.510~512 (2005)
- Párraga HC, "Acute dystonia after stimulant discontinuation in 2 ADHD children receiving aripiprazole", J Clin Psychopharmacol, 35, pp.480~481 (2015)
- Doğan Y, "Acute dystonia due to discontinuing of methylphenidate treatment : a case", Psychiatry Clin Psychopharmacol, 28, pp.119~ (2018)
- Guler G, "Dystonia in an adolescent on risperidone following the discontinuation of methylphenidate : a case report", Clin Psychopharmacol Neurosci, 13, pp.115~117 (2015)
- Efron D, "Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder : a double-blind, crossover trial", Pediatrics, 100, pp.662~666 (1997)
- Wenthur CJ, "Classics in chemical neuroscience : methylphenidate", ACS Chem Neurosci, 7, pp.1030~1040 (2016)
- Rusyniak DE, "Neurologic manifestations of chronic methamphetamine abuse", Psychiatr Clin North Am, 36, pp.261~275 (2013)
- Schneider SA, "Recurrent acute dystonic reaction and oculogyric crisis despite withdrawal of dopamine receptor blocking drugs", Mov Disord, 24, pp.1226~1229 (2009)
- Gray JD, "Methylphenidate administration to juvenile rats alters brain areas involved in cognition, motivated behaviors, appetite, and stress", J Neurosci, 27, pp.7196~7207 (2007)
- Charlot LR, "Psychotropic medications use and side effects of individuals with intellectual and developmental disabilities", J Intellect Disabil Res, 64, pp.852~863 (2020)